ChemotherapyFDA-approvedFirst-line
Docetaxel
How it works
Interferes with cell division, causing cancer cells to die.
Cancer types
Efficacy
In clinical trials, docetaxel significantly improved overall survival and delayed disease progression in patients with metastatic castration-resistant prostate cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Setidegrasib and Docetaxel for Non-small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Ivonescimab with Chemotherapy in Early-Stage Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing Docetaxel for Prostate Cancer After Radiation Therapy | Prostate Cancer | phase-2 | — | Source → |
| Comparing Two Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-3 | Median prostate cancer-specific survival from the initiation of DTX was 16.1 months in the ENZ-DTX group and 25.3 months in the ABI-DTX group. | Source → |
| Testing Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| New Insights into Cancer Treatment with Sacituzumab Govitecan | Lung Cancer | phase-3 | Median overall survival with sacituzumab govitecan versus docetaxel was 8.9 versus 9.8 months (hazard ratio [HR] = 0.96, 95% CI: 0.68-1.38) and 11.8 versus 10.7 months (HR = 0.89, 95% CI: 0.60-1.32) in subgroups with Trop-2 histological scores greater than or equal to the median and less than the median, respectively. | Source → |
| Researchers Investigate Combination Therapy for Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Testing Ceralasertib and Durvalumab in Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Eribulin vs. Taxanes for HER2-Positive Breast Cancer | Breast Cancer | phase-3 | Progression-free survival was 14.0 months with eribulin vs. 13.1 months with docetaxel, and 14.1 months with eribulin vs. 10.8 months with paclitaxel. | Source → |
| New Treatment Options for Lung Cancer Patients | Lung Cancer | observational | The disease control rate was significantly higher in patients receiving PD-1 blockade-based regimens at 82.8% compared with 54.0% in the control group. | Source → |
| Testing a New Treatment for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing New Combination Therapy for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Docetaxel Side Effect in Breast Cancer Patients | Breast Cancer | review | — | Source → |
| Evaluating Treatment Intensification for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Tislelizumab Improves Outcomes in Advanced Lung Cancer | Lung Cancer | phase-3 | The median overall survival was 16.9 months versus 11.9 months for tislelizumab versus docetaxel in the ITT population. | Source → |
| Sotorasib Outperforms Docetaxel in Lung Cancer Treatment | Lung Cancer | observational | Sotorasib was associated with a 36.7% decreased risk of death and a 43.3% decreased risk of treatment discontinuation or death compared to docetaxel. | Source → |
| Breast Cancer Cells Less Sensitive to Chemotherapy Due to Specific RNA | Breast Cancer | lab-study | — | Source → |
| Testing Radium-223 with Docetaxel in Prostate Cancer Patients | Prostate Cancer | phase-3 | — | Source → |
| New Study Examines Effectiveness of Docetaxel Plus Ramucirumab After Immunotherapy for Lung Cancer | Lung Cancer | phase-2 | The objective response rate was 33.3% (90% CI, 19.9-49.1), and the disease control rate was 90.9% (90% CI, 78.1-97.5). | Source → |
| Real-World Outcomes of Docetaxel in Lung Cancer Patients | Lung Cancer | observational | Median overall survival was 6.5 months (95% CI, 5.9-7.3). | Source → |
| Evaluating a New Treatment Combination for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Study Examines Effectiveness of Docetaxel and Ramucirumab for Lung Cancer Symptoms | Lung Cancer | observational | The pleural effusion control rate was 87%, and the cerebral edema control rate was 26%. | Source → |
| Testing BNT324 for Metastatic Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing Combination Therapy for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| ONC-392 vs Docetaxel for Lung Cancer That Has Progressed | Lung Cancer | phase-3 | — | Source → |
| Testing New Treatments for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a Combination of Medications for HER2-Positive Early-Stage Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Study of Darolutamide in Combination with Androgen Deprivation Therapy and Docetaxel for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Comparing a New Treatment to Docetaxel for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Comparing BL-B01D1 to Docetaxel in Lung Cancer Treatment | Lung Cancer | phase-3 | — | Source → |
| Evaluating a Lower-Dose Chemotherapy Combination for Older Women with Early-Stage Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Green Tea and Quercetin Combined with Chemotherapy in Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Testing ADI-PEG 20 with Gemcitabine and Docetaxel for Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing Ivonescimab with Docetaxel for Advanced Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing New Treatment for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Docetaxel with Hormonal Therapy and Apalutamide for Metastatic Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Comparing Treatments for Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| New Treatment Combination Shows Promise for Prostate Cancer Patients | Prostate Cancer | phase-2 | At week 12, 67.7% of patients showed a response in prostate-specific antigen (PSA) levels. | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone and Antiandrogen Therapy for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| New Treatment Combination Shows Promise for HER2 Positive Breast Cancer | Breast Cancer | phase-3 | Overall survival was longer in the pyrotinib group (hazard ratio 0.64 (95% confidence interval (CI) 0.46 to 0.89); nominal one-sided P=0.004). | Source → |
| Evaluating Nivolumab and Docetaxel for Advanced Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Study of a New Medicine for Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| New Insights into Prostate Cancer Treatment Options | Prostate Cancer | meta-analysis | Darolutamide + docetaxel + ADT showed significant benefit over docetaxel + ADT, ADT and standard-nonsteroidal-antiandrogen + ADT in all analyses. | Source → |
| New Insight into Docetaxel Resistance in Prostate Cancer | Prostate Cancer | lab-study | Treatment with an OTUB2 inhibitor resensitized resistant CRPC to docetaxel. | Source → |
| PIGL's role in prostate cancer resistance to docetaxel treatment | Prostate Cancer | lab-study | — | Source → |
| Liposomes Help Deliver Cancer Medicine to Prostate Cancer Cells | Prostate Cancer | review | — | Source → |
| Combination Therapy for Lung Cancer May Have Different Side Effects | Lung Cancer | observational | — | Source → |
| Severe Neutropenia Risk in Prostate Cancer Patients on Cabazitaxel | Prostate Cancer | observational | — | Source → |
| Eugenol Derivatives Enhance Chemotherapy Effectiveness in Prostate Cancer Cells | Prostate Cancer | lab-study | — | Source → |
| Chemotherapy Combination Affects Lung Cancer Cells in Lab Experiments | Lung Cancer | lab-study | — | Source → |
| Hospitalization Risks Vary for Prostate Cancer Patients on Different Treatments | Prostate Cancer | observational | — | Source → |
| Early Docetaxel and Enzalutamide for Prostate Cancer: New Insights | Prostate Cancer | phase-3 | Among those assigned no enzalutamide, OS was longer with the planned use of early docetaxel (HR 0.90, 95% CI 0.82-0.98), especially in high-volume disease. | Source → |
| METTL14's Role in Lung Cancer Progression and Docetaxel Resistance | Lung Cancer | lab-study | — | Source → |
| Atezolizumab Compared to Docetaxel in Lung Cancer Treatment | Lung Cancer | meta-analysis | Atezolizumab had better efficacy than docetaxel for overall survival (HR: 0.77, 95% CI: 0.73 to 0.81). | Source → |
| New Nanoparticle Delivery System Shows Promise for Breast Cancer Treatment | Breast Cancer | lab-study | The cRGD-HA-CDU@DTX system exhibited a 64.12% tumor growth reduction. | Source → |
| New Delivery System for Cancer Drug Shows Promise | Prostate Cancer | lab-study | Docetaxel-bound nanoparticles significantly reduced the viability of the tumor cell compared to the healthy cell in a dose-dependent manner, especially at 24 (50.14 ± 13.25 to 22.32 ± 5.51 at 100 µg/mL) h and 48 (41.46 ± 2.22 to 18.80 ± 2.81 at 100 µg/mL) h. | Source → |
| New Nanofibrous Mats Deliver Cancer-Fighting Medicine Directly to Prostate Cancer Sites | Prostate Cancer | lab-study | — | Source → |
| Prostate Cancer Cells May Resist Chemotherapy Due to Protein Interactions | Prostate Cancer | lab-study | — | Source → |
| AGD1 Complex May Reduce Effectiveness of Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| Traditional Chinese Medicine May Help Overcome Prostate Cancer Resistance to Treatment | Prostate Cancer | lab-study | — | Source → |
| Real-world safety of docetaxel for lung cancer treatment | Lung Cancer | observational | — | Source → |
| DRG2 levels predict response to PARP inhibitors in prostate cancer cells | Prostate Cancer | lab-study | — | Source → |
| Cancer Cells Develop Resistance to Chemotherapy | Breast Cancer | lab-study | — | Source → |
| GRIM-19's Role in Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| New way to deliver cancer drug may reduce side effects | Breast Cancer | lab-study | The encapsulated drug indicated higher cytotoxicity on MCF-7 cells and the half inhibitory concentration (IC) value was 2 µg/ml after 72 h. | Source → |
| Prostate Cancer Cells May Resist Treatment Due to Exosome-Released Molecule | Prostate Cancer | lab-study | — | Source → |
| Liquid Biopsy Predicts Treatment Response in Prostate Cancer Patients | Prostate Cancer | phase-3 | LBRB-positive patients had no benefit from continuing enzalutamide with docetaxel (HR = 0.78, 95% CI = 0.41-1.48, p = 0.44; RMST: 7.9 vs 7.1 mo, p = 0.50). | Source → |
| Researchers Identify Pathway Behind Docetaxel Resistance in Prostate Cancer Cells | Prostate Cancer | lab-study | — | Source → |
| Targeted Nanoparticles Show Promise in Treating Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Combining drugs to overcome cancer resistance | Lung Cancer | lab-study | — | Source → |
| Cost-Effectiveness of Sotorasib for Lung Cancer Patients in China | Lung Cancer | phase-3 | — | Source → |
| Dexamethasone May Help Reduce Hand-Foot Syndrome in Breast Cancer Patients | Breast Cancer | observational | Development of all-grade hand-foot syndrome in all treatment cycles was significantly lower in the 8 mg group (50.0%) than in the 4 mg group (73.0%). | Source → |
| Previous Cancer Treatment May Affect Neutropenia Risk in Lung Cancer Patients | Lung Cancer | phase-2 | — | Source → |
| Targeting Glutamine Metabolism in Resistant Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Prostate Cancer Protein Degradation May Help Combat Resistance to Docetaxel | Prostate Cancer | lab-study | — | Source → |
| Docetaxel treatment creates large, polyploid cancer cells in ovarian cancer | Ovarian Cancer | lab-study | — | Source → |
| Combining Turmeric Compound with Standard Prostate Cancer Treatment May Improve Effectiveness | Prostate Cancer | lab-study | — | Source → |
| NOTCH3 linked to docetaxel resistance in prostate cancer | Prostate Cancer | lab-study | — | Source → |
| Combining two drugs slows prostate cancer growth in lab experiments | Prostate Cancer | lab-study | The combination of CUDC-101 and DTX significantly reduced tumor growth, as evidenced by lower tumor weight and volumes. | Source → |
| Symptoms of Breast Cancer Patients Before and After Chemotherapy | Breast Cancer | observational | — | Source → |
| New Lung Cancer Treatment Combination Shows Mixed Results | Lung Cancer | phase-3 | The clinical benefit rate was 75.5% for sitra + nivo and 64.5% for docetaxel. | Source → |
| Combining Cancer Treatments for Prostate Cancer: What's the Best Combination? | Prostate Cancer | review | — | Source → |
| Abiraterone Acetate May Be Better Than Docetaxel for Prostate Cancer | Prostate Cancer | observational | The abiraterone acetate group demonstrated significantly better progression-free survival (PFS) than the docetaxel group (not reached vs. 15.1 months: hazard ratio = 0.37; 95% confidence interval = 0.28-0.50; P < .001). | Source → |
| New Cancer Treatment Combination Tested in Ovarian Cancer Patients | Ovarian Cancer | phase-1 | — | Source → |
| Polysaccharides from Lentinus edodes may help prostate cancer treatment | Prostate Cancer | lab-study | — | Source → |
| Dexamethasone May Reduce Oral Mucositis in Breast Cancer Patients | Breast Cancer | observational | The incidence of all-grade oral mucositis in the first cycle was 57.8% in the low-dose group and 19.2% in the high-dose group. | Source → |
| New Carrier Material Helps Deliver Cancer Drugs More Effectively | Ovarian Cancer | lab-study | TPGS-CHMC/DTX micelles displayed significantly higher anti-tumour activity and less toxicity than the free DTX solution. | Source → |
| Link Found Between Resistance to Two Prostate Cancer Drugs | Prostate Cancer | lab-study | — | Source → |
| Understanding Resistance to Prostate Cancer Treatments | Prostate Cancer | review | — | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-3 | The median time to castration-resistant prostate cancer in patients treated with ABI was significantly longer compared to those treated with DOC (42 vs. 22 months; p = 0.006). | Source → |
| Ramucirumab plus docetaxel for lung cancer after immunotherapy | Lung Cancer | review | The pooled weighted median progression-free survival was 5.7 months, and the median overall survival was 11.2 months in the RAM + DTX ICI pre-treated group. | Source → |
| Generic vs. Brand Docetaxel in Breast Cancer Treatment | Breast Cancer | observational | — | Source → |
| Docetaxel Inhibits Prostate Cancer Cell Growth | Prostate Cancer | lab-study | — | Source → |
| Triplet Therapy Shows Promise for Prostate Cancer Treatment | Prostate Cancer | meta-analysis | Triplet therapy with darolutamide or abiraterone with docetaxel and ADT improved overall survival, with a hazard ratio of 0.70 (95%CI 0.61-0.80) compared to docetaxel+ADT. | Source → |
| Reusing a Cancer Treatment May Help Some Prostate Cancer Patients | Prostate Cancer | observational | Among 54 evaluable patients, 27.8% had a PSA decline ≥50%. | Source → |
| Continuing Enzalutamide May Delay Cancer Progression in Some Patients | Prostate Cancer | phase-3 | — | Source → |
| Exosomal RNA May Contribute to Prostate Cancer Resistance to Docetaxel | Prostate Cancer | lab-study | — | Source → |
| Fucoidan May Help Treat Docetaxel-Resistant Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Docetaxel Response Affects Cabazitaxel Sensitivity in Prostate Cancer | Prostate Cancer | observational | None of the patients with a poor response to prior docetaxel therapy responded well to cabazitaxel therapy. | Source → |
| Docetaxel for Early Prostate Cancer: New Long-Term Results | Prostate Cancer | phase-3 | The 5-year metastasis-free survival rate was 82% with SOC plus docetaxel vs 77% with SOC. | Source → |
| Abiraterone and Docetaxel Compared in Prostate Cancer Treatment | Prostate Cancer | observational | The ABI group had a significantly better castration-resistant prostate cancer (CRPC)-free survival than the DOC group [hazard ratio (HR), 0.53; 95% confidence interval (CI), 0.34-0.82]. | Source → |
| New Lung Cancer Treatment Combination Shows Promise in China | Lung Cancer | phase-2 | The median progression-free survival was 5.8 months, and the progression-free survival rates at 6 and 12 months were 48% and 30%, respectively. | Source → |
| Docetaxel Works Similarly in Two Types of Prostate Cancer Patients | Prostate Cancer | lab-study | — | Source → |
| New Cancer Gene Linked to Resistance to Common Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| Adding Docetaxel or Abiraterone to Prostate Cancer Treatment May Improve Survival | Prostate Cancer | phase-3 | Patients receiving upfront ABI had significantly better CRPCFS than those receiving ADT/CAB or upfront DOC [hazard ratio (HR) 0.39; 95% CI 0.27-0.56]. | Source → |
| Nintedanib and Docetaxel May Help Some Lung Cancer Patients | Lung Cancer | observational | Each patient achieved a partial response with nintedanib plus docetaxel, with response duration from 8 months to over 30 months. | Source → |
| BMI's Effect on Docetaxel Outcomes in Prostate Cancer Patients | Prostate Cancer | phase-3 | Overweight and obese patients had significantly better overall survival compared with lean patients, with hazard ratios of 0.68 and 0.59, respectively. | Source → |
| Chemotherapy's Short-Term Impact on Prostate Cancer Patients | Prostate Cancer | phase-3 | FACT-P scores decreased in Arm A at the end of treatment and remained unchanged in Arm B (p<0.0001). | Source → |
| Docetaxel and Hormone Therapy Tested in Prostate Cancer Patients | Prostate Cancer | phase-2 | The median CRPC-free survival was 26.4 months with a one-year CRPC-free rate of 79%. | Source → |
| Researchers Explore How Cancer Cells Resist Treatment | Lung Cancer | lab-study | — | Source → |
| New Chemotherapy Combination Shows Promise in Treating Triple-Negative Breast Cancer | Breast Cancer | phase-2 | 61.4% of patients in the DCb group achieved a pathologic complete response. | Source → |
| Prostate Cancer Study Links Blood Test Ratio to Treatment Outcomes | Prostate Cancer | observational | The median progression-free survival was 9.8 vs 7.5 months, and overall survival was 17.6 vs 14.2 months in patients with a lower vs higher neutrophil-to-lymphocyte ratio. | Source → |
| Different Response to Cancer Treatment in Two Types of Tumors | Lung Cancer | observational | — | Source → |
| Docetaxel Affects Ovarian Cancer Cells' Structure and Strength | Ovarian Cancer | lab-study | When the concentration of docetaxel was 100 ng/ml, the adhesion decreased by 37.04% and Young's modulus increased by 1.57 times compared with the control group. | Source → |
| G-CSF May Help Reduce Severe Side Effects in Breast Cancer Patients | Breast Cancer | observational | The rate of febrile neutropenia was 6.2% in the G-CSF group compared to 15.7% in the non-G-CSF group. | Source → |
| DRG2 levels affect how prostate cancer cells respond to docetaxel | Prostate Cancer | lab-study | In PC3 and DU145 cell lines, DRG2 knockdown increased docetaxel-induced Annexin V (+) apoptosis by 8.7 and 2.7 times, respectively. | Source → |
| Modeling Tumor Growth in HER2-Negative Breast Cancer Patients | Breast Cancer | phase-2 | — | Source → |
| Tau protein buildup makes prostate cancer cells more sensitive to treatment | Prostate Cancer | lab-study | — | Source → |
| Gold Nanoparticles Deliver Cancer Drug to Prostate Cancer Cells | Prostate Cancer | lab-study | The drug encapsulated nanoformulations reduced the cell viability to about 40% at 40 µM concentration after 24, 48, and 72 hours of treatment. | Source → |
| Predicting Docetaxel Side Effects in Prostate Cancer Patients | Prostate Cancer | phase-3 | — | Source → |
| Atezolizumab May Help Lung Cancer Patients with Certain Genetic Mutations | Lung Cancer | phase-3 | Median overall survival was 7.3 months in the atezolizumab group versus 5.8 months in the docetaxel group. | Source → |
| 4-Weekly Docetaxel Treatment for Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Researchers Explore New Way to Make Prostate Cancer Treatment More Effective | Prostate Cancer | lab-study | — | Source → |
| Docetaxel Rechallenge May Improve Survival in Prostate Cancer Patients | Prostate Cancer | observational | The median overall survival was 50.11 months in the rechallenge group, as compared to 26.36 months in the non-rechallenge group. | Source → |
| Chemotherapy after Prostate Cancer Treatment: New Insights | Prostate Cancer | meta-analysis | The meta-analysis showed a slightly OS improvement (HR: 0.79; 95% CI, 0.63-0.98; p = 0.03) with docetaxel. | Source → |
| Targeted Cancer Treatment Using Nanoparticles | Prostate Cancer | lab-study | The nanoparticles showed 2.79-fold lower IC values than free docetaxel. | Source → |
| Testosterone Levels May Influence Effectiveness of Prostate Cancer Treatment | Prostate Cancer | phase-3 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.